970 related articles for article (PubMed ID: 28404069)
1. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Curry MP; O'Leary JG; Bzowej N; Muir AJ; Korenblat KM; Fenkel JM; Reddy KR; Lawitz E; Flamm SL; Schiano T; Teperman L; Fontana R; Schiff E; Fried M; Doehle B; An D; McNally J; Osinusi A; Brainard DM; McHutchison JG; Brown RS; Charlton M;
N Engl J Med; 2015 Dec; 373(27):2618-28. PubMed ID: 26569658
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Younossi ZM; Stepanova M; Gordon S; Zeuzem S; Mann MP; Jacobson I; Bourliere M; Cooper C; Flamm S; Reddy KR; Kowdley K; Younossi I; Hunt S
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):567-574.e6. PubMed ID: 29155352
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Sucher AJ; Hemstreet BA
Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.
Younossi ZM; Stepanova M; Sulkowski M; Wyles D; Kottilil S; Hunt S
Liver Int; 2017 Dec; 37(12):1796-1804. PubMed ID: 28470938
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Younossi ZM; Stepanova M; Jacobson IM; Asselah T; Gane EJ; Lawitz E; Foster GR; Roberts SK; Thompson AJ; Willems BE; Welzel TM; Pearlman B; Younossi I; Racila A; Henry L
Aliment Pharmacol Ther; 2018 Jan; 47(2):259-267. PubMed ID: 29181842
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Foster GR; Afdhal N; Roberts SK; Bräu N; Gane EJ; Pianko S; Lawitz E; Thompson A; Shiffman ML; Cooper C; Towner WJ; Conway B; Ruane P; Bourlière M; Asselah T; Berg T; Zeuzem S; Rosenberg W; Agarwal K; Stedman CA; Mo H; Dvory-Sobol H; Han L; Wang J; McNally J; Osinusi A; Brainard DM; McHutchison JG; Mazzotta F; Tran TT; Gordon SC; Patel K; Reau N; Mangia A; Sulkowski M; ;
N Engl J Med; 2015 Dec; 373(27):2608-17. PubMed ID: 26575258
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Greig SL
Drugs; 2016 Oct; 76(16):1567-1578. PubMed ID: 27730529
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Everson GT; Towner WJ; Davis MN; Wyles DL; Nahass RG; Thuluvath PJ; Etzkorn K; Hinestrosa F; Tong M; Rabinovitz M; McNally J; Brainard DM; Han L; Doehle B; McHutchison JG; Morgan T; Chung RT; Tran TT
Ann Intern Med; 2015 Dec; 163(11):818-26. PubMed ID: 26551051
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]